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The major histocompatibility complex (MHC)' has been shown to play an important
and probably essential role in the immune systems of a number of animal species ranging
from mouse to man (1-3) . The murine MHC known as the H-2 complex has been divided
into four major regions, and include two serological regions known as H-2K and 11-21) or K
and D, which are separated by two other regions designed I and S (4) . The K andD regions
determine the strong serologically detectable transplantation antigens of the mouse,
which seem to be important as the target antigens for T-cell-mediated lympholysis (5-10) .
The S region is positioned adjacent to and to the left of the D region with respect to the
centromere . It determines the levels of a serum alpha globulin known as Ss as well as a
sex-linked allotypic variant of Ss designated Slp (11) . Genes mapping within the I region
designated Ir or immune response genes, are located between K and S, and control
immune response potential to a number of synthetic and natural immunogens (for review
see 12-14) . Recent Ir-gene (15-17) and Ia-antigen (18-21) studies in B10.A recombinant
mouse strains have led to the division of the Iregion into three regions designated I-A, I-B,
and I-C (22) . At the present time, therefore, the H-2 complex is clearly divisible into six
regions: K, I-A, 1-13, I-C, S, and D .
Some of the immunological functions attributed to MHC genes have been demon-
strated by employing allogeneic grafting or cell combinations between incompatible
partners . Although such procedures are necessary for detecting alloantigens, it is unlikely
that these immunological phenomena as well as the antigenic differences they reflect were
naturally selected in evolution for the purpose of allogeneic immune reactions .
The results presented in this report demonstrate that murine T-cell-mediated
cytotoxic effector lymphocytes generated in vitro by sensitization to trinitro-
phenyl (TNP)-modified autologous spleen cells (23) are specific for TNP-modi-
fied target cells expressing K and/orD serological specificities identical to those
of the modified stimulating cells . Furthermore, the differential response patterns
observed to TNP-modified K- and D-region products by responding lymphocytes
of mice expressing k alleles in K and I regions suggest that H-2-linked Ir genes
' Abbreviations used in this paper: BSS, Hanks' balanced salt solution ; MHC, major histocom-
patibility complex ; SD, serologically defined ; TNBS, 2,4,6-trinitrobenzene sulfonate ; TNP, trini-
trophenyl .
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may be controlling response potential to new cellular antigenic determinants
resulting from TNP modification of theKand D serological specificities . These
findings necessitate a fresh examination of certain functional aspectsof the genes
associated with theMHC by involving them in an autologous model .A syngeneic
functional role for the cell surface products controlled by the K andD regions is
considered .
Materials and Methods
Mice .
￿
All mice used in the experiments were males, 7-9 wk of age . The B10 congenic strains were
purchased from Jackson Laboratories, Bar Harbor, Maine . The B10.A(2R), B10.A(4R), and
B10.A(5R) recombinant lines were raised in our mouse colony from breeders obtained either from
Jackson Laboratories or from Dr . Donald Shreffler, Department ofHuman Genetics, University of
Michigan, Ann Arbor, Mich . TheA.TL and A.TH mice were raised in our mouse colony from breeders
obtained from Dr. Donald Shreffler. Other inbred strains were obtained from the NIH Animal
Production facility, Bethesda, Md .
TNPModification of Spleen Cells .
￿
Cells to be modified with TNP were prepared from the spleen
of young adult mice by gentle washing with blunt forceps, aspirating through a syringe in Hanks' bal-
anced salt solution (BSS), and filtering through nylon mesh to remove clumps and debris. Erythro-
cytes were lysed by a 2 min exposure of the cell suspension to ammonium chloride lysing buffer, fol-
lowed by washing in BSS. The cell pellet was suspended in a phosphate-buffered solution containing
10 mM 2,4,6-trinitrobenzene sulfonate (TNBS) (Pierce Chemical Co ., Rockford, Ill .), pH 7 .3 at a
volume:volume ratio of cells to reagent of 1:4 . The cell-reagent mixture was incubated at 37°C for 10
min and then washed twice inBSS containing fetal bovine serum . Spleen cells to be used for sensitiza-
tion and for targets were modified with TNBS in an identical fashion . Cells to be used as cytotoxic
targets were labeled with [ 5'Cr]Na,Cr0 4 (Amersham/Searle Corp ., Arlington Heights, Ill .) for 30 min
at 37°C before modification with TNBS .
In Vitro Cell Culture and Assay for Cytotoxic Effector Cells .
￿
Splenic lymphocytes were sensi-
tized in vitro with TNP-modified cells as previously described (23) by the Mishell and Dutton proce-
dure (24) . After a 5 day incubation period, effector cells were harvested and their cytotoxic reactivity
was determined by a modification of the method of Canty and Wunderlich (25) . The mean and stan-
dard error of the percentage of specific cytotoxicity was calculated as described elsewhere (26) .
Blocking of Effector Phase with Nonradioactive, TNP-Modified Target Cells .
￿
Nonradioactive
splenic target cells sharing K- and/or D-end specificities with cells of the stimulating phase were
preincubated with B10.BR effector lymphocytes for 30 min before addition of 5'Cr-labeled,
TNP-modified target cells in the 4-h cytotoxic phase . The ratios of unlabeled to "Cr-labeled target
cells were 5 :1, 10:1, and 20 :1 . The unlabeled targets were maintained in the effector- 5'Cr-labeled
target cell mixture throughout the effector phase .
Results
Effector Cell Specificity Using TNP-Modified Spleen Target Cells .
￿
An earlier
report demonstrated that in vitro induction of T-cell-mediated lympholysis to
TNP-modified autologous spleen cells resulted in the generation of effector
lymphocytes which lysed TNP-modified syngeneic target cells, but not TNP-
modified H-2-nonrelated congenic targets (23) . However, modified target cells
which shared H-2K-end specificities with the responder and stimulating cells
were lysed . These results and the subsequent preliminary reports (27, 28)
suggested that a part of the effector cell specificity was directed against
TNP-altered cell surface components controlled by genes mapping within the
H-2 complex. In orderto verify the initialobservations and to map within H-2 the
genes controlling the cellular components modified by TNP, splenic lymphocytes
from B10.A, B10.BR, B10.D2, and C57BL/10 donors were sensitized in vitrowith
TNP-modified autologous spleen cells. The effector cells generated 5 days later1350
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were tested on unmodified and TNP-modified syngeneic target spleen cells, as
well as on a number of modified congenic, allogeneic, and recombinant splenic
targets which share certain intra-H-2 alleles with the responding andstimulating
cells . In order to minimize any possible antigenic differences that might exist
between TNP-modified stimulating and target cells, these experiments em-
ployed TNP-modified normal spleen cells as targets rather than H-2-matched
tumor targets or syngeneic, mitogen-induced splenic blasts . The spontaneous
"Cr release from TNP-modified spleen cell targets in the 4-h lytic phase ranged
between 21 and 43% . Results representative of these effector cell specificity
experiments are summarized in the first four tables of this report . Depending on
the availability of target cell donors each combination was verified 2-20 times.
The first three columns of these tables indicate the strains of the responding,
stimulating, and target cells, respectively . The H-2alleles for the various regions
ofH-2 are shown beneath each strain . The fourth column gives the mean percent
of specific cytotoxicity with standard errors of the means. The last column
indicates the H-2region common betweenthe target cells and the respondingand
stimulating cells .
Results obtained by testing effector cells generated from cultures of B10.A-
responding and B10.A-TNP-stimulating cells on the different targets are
summarized in Table I . B10.A effector cells did not lyse unmodified B10.A
targets, whereas they did lyse TNP-modified B10.A targets . This verifies that
modification of the syngeneic target cell is necessary in order to obtain
cytotoxicity . Modified 1310.A(2R), which shares all known H-2 regions except D ;
1310.1311 which shares K, I-A, and I-B ; and B10.A(4R) which shares K and I-A
with B10.A were all effective targets for detecting lympholysis by the B10.A
effectors . These results indicate that at least part of the specificity of the B10.A
effector cells is directed against TNP-modified cell surface components con-
trolled by K or K plus I-A . In contrast, TNP-modified B10.D2 and B10.A(5R)
which share I-C, S andD; A.TL which shares I-A, I-B, and D ; C_ 57BL/10 which
share no known H-2 regions; and B10.HTG and C3H.OH which share I-C andS
with the responding and stimulating cells were all ineffective targets . These
findings indicate that the cytotoxicity of the B10.A effectors was not directed
against the D end and was exclusively specific for the K end .
Effector cells generated from cultures of 1310.1311 lymphocytes sensitized with
B10.BR-TNP spleen cells were also tested on a series of TNP-modified targets .
This strain shares K-end H-2 alleles (i.e ., K, I-A, and I-B) with B10.A, but differs
in the D-end alleles (I-C, S, and D) . Representative results, using targets
identical to those used to test B10.A effector cells are summarized in Table 11 .
Modification of syngeneic targets was necessary in order to obtain cytotoxicity .
B10.A-TNP and B10.A(2R)-TNP targets, which share K-end alleles with
1310.811, were lysed as effectively as syngeneic B10.BR-TNP targets. C3H.OH-
TNP targets which share only the H-21)-region allele with the responding and
stimulating cells were not lysed. A.TL-TNP targets, which appear to share all
H-2 regions with 1310.1311 except theKand D serological regions, were ineffective
targets . The other three strains shown which share no known H-2 alleles with
1310 .1311 were not lysed. These results indicate that 1310 .1311 lymphocytes
sensitized with TNP-modified syngeneic spleen cells respond to the TNP-modi-GENE M . SHEARER, TERRY G . REHN, AND CAROL A . GARBARINO
TABLE I
In Vitro Induction of Cytotoxicity ofB10.A Spleen Cells to TNP-Modified Autologous
Spleen Cells Assayed with TNP-Modified Syngeneic, Congenic, Allogeneic, or
Recombinant Spleen Target Cells
Responding
cells
B10.A
kkkddd
Effectontarget cell ratio, 20:1
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fiedKorKplus 1-A regions andnot to the modified D allele . Thus, the pattern of
specificity observed for the 1310.1311 effector cells is identical to that noted for
1310.A effectors (Table I), i .e . lymphocytes from both strains responded to K-end
modification (which are identical), but not to their respective (and different)
modifiedD alleles .
In contrast to 1310.1311, the 1310.D2 strain shares the D end (I-C, S, D,) with
1310.A . It was of interest to test the specificity of 1310.D2 effector cells generated
in the TNP-modified autologous system, particularly since 1310.A effector cells
did not respond to TNP-modified H-2D d-allele products . The results, shown in
Stimulating
cells Target cells Specific
lysis f SE
Target cell H-2 region common
to responding and stimulating
cells
B10.A-TNP BMA -3 .2 t 2 .0 All ofH-2
kkkddd kkkddd
B10.A-TNP 28.6 t 3.9 All ofH-2
kkkddd
B10.A(2R)-TNP 34 .3 t 6.4 K, I-A, I-B, I-C, S
kkkddb
B10.BR-TNP 31 .5 t 2.5 K, I-A, I-B
kkkkkk
B10.A(4R)-TNP 37.3 f5.0 K, I-A
kkbbbb
B10.D2-TNP 3.9 t2.0 I-C, S, D
dddddd
BMA(5R) 3.0 t 1.4 I-C, S, D
bbbddd
A.TL-TNP 3.9 t 4.8 I-A, I-B,D
skkkkd
C57BL/10-TNP 3.1 t 2.5 None
bbbbbb
B10.HTG-TNP 2 .4 t 3.0 I-C, S
dddddb
C3H.OH-TNP 1 .9 ::E 3.1 I-C,S
dddddk1352
TABLE II
In Vitro Induction of Cytotoxicity ofBIO.BR Spleen Cells to TNP-Modified Autologous
Spleen Cells Assayed with TNP-Modified Syngeneic, Congenic, Allogeneic, or
Recombinant Spleen Target Cells
Effectorfarget cell ratio, 20 :1
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Table III, again indicate that TNP modification of the syngeneic targets is neces-
sary to obtain lysis. The various TNP-modified targets lysed by the B10.D2 ef-
fector cells were B10.D2, B10.A, B10.A(5R), A.TL, and C3KOH. The modified
targets in which significant lysis was not obtained include B10.A(2R), B10.BR,
and B10.A(4R) . In contrast to the results obtained with B10.A and B10.BR,
B10.D2 lymphocytes responded to TNP-modified D serological region, and in
fact, to the same modified D-end allele to which B10.A did not respond (compare
results in Tables I and III using A.TL-TNP targets) . This difference in response
to the TNP-modified H-2D d-allele by B10.A and B10.D2 raises the possibility of
H-2-linked Ir genes (see Discussion) . The B10.D2 effector cells also responded to
one or more TNP-modified H-2 alleles other than H-2D, as shown by the 14.7%
lysis obtained with C3H.OH-TNP targets . Disregarding specificity, the B10.D2
effectors generally gave lower cytotoxic levels than did the B10.A and B10.BR
effector cells. Modified targets . which share no known regions of H-2 with cells
Responding
cells
Stimulating
cells Target cells Specific
lysis t SE
Target cell H-2 region common
to responding and stimulating
cells
B10.BR B10.BR-TNP B10.BR -4 .0 t 1 .9 All of H-2
kkkkkk kkkkkk kkkkkk
B10.BR-TNP 33 .2 t 3.0 All ofH-2
kkkkkk
B10.A-TNP 31 .5 t 2.5 K, I-A,1-B
kkkddd
11 B10.A(2R)-TNP 26.9 t2.2 K, I-A, I-B
11 11 kkkddb
C3H.OH-TNP 2 .1 t 2.1 D
dddddk
11 11 A.TL-TNP -2 .2 t 2.2 I-A, I-B, I-C, S
11 skkkkd
A.TH-TNP -0 .4 f 1.3 None
sssssd
11 11 SJL-TNP -0 .7 t 1 .2 None
ssssss
B10.132-TNP -2 .2 t 2 .4 None
ddddddGENE M. SHEARER, TERRY G. REHN, AND CAROL A . GARBARINO
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of the sensitizing phase show no significant lysis, e.g ., B10.BR-TNP and
B10.A(4R)-TNP, or reduced lysis as in the case of C57BL/10-TNP . The latter
targets were lysed 11 .0 zE 2.9% by B10.D2 effectors, which is of questionable
significance .
The C57BL/10 strain, which does not share any known H-2 alleles with the
congenic lines tested above, was also tested for effector cell specificity . The
results of representative experiments are summarized in Table IV . The TNP-
modified targets that detected high levels of effector lympholysis were C57BL/10,
B10.A(5R), B10.A(4R), and B10.A(2R), as well as the noncongenic but H-
2-matched C3H.SW . The positive results obtained usingB10.A(5R)-TNP targets
map some of the specificity to modified K-end products, whereas the 24.5 and
TABLE III
In Vitro Induction of Cytotoxicity ofB10.D2 Spleen Cells to TNP-Modified Syngeneic
Spleen Cells Assayed with TNP-Modified Syngeneic, Congenic, Allogeneic, or
Recombinant Spleen Target Cells
Effector:target cell ratio, 20 :1
Responding
cells
Stimulating
cells
Target cells
Specific
lysis t SE
Target cell H-2 region common
to responding andstimulating
cells
B10.D2 B10.D2-TNP MOM -2.4 t 2.8 All of H-2
dddddd dddddd dddddd
11 B10.D2-TNP 19.2 t 2.4 All of H-2
11 dddddd
B10.A-TNP 17.6 t 3.6 I-C, S,D
kkkddd
B10.A(5R)-TNP 12 .8 f 2.1 I-C, S,D
11 11 bbbddd
11 B10.A(2R)-TNP 0.8 t 1.6 I-C, S
kkkddb
A.TL-TNP 15 .6 t 3.7 D
11 11 skkkkd
C3H.OH-TNP 14 .7 t 1 .2 K, I-A,1-B, I-C, S
dddddk
11 11 B10.BR-TNP 2.4 t 0.6 None
11 11 kkkkkk
C57BL/10-TNP 11 .0 t 2.9 None
bbbbbb
11 B10.A(4R)-TNP 5.0 t 3.1 None
11 11 kkbbbb1354
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TABLE IV
In VitroInduction of Cytotoxicity of C57BL/10 Spleen Cells to TNP-ModifiedAutologous
Spleen Cells Assayed with TNP-Modified Syngeneic, Congenic, Allogeneic, or
Recombinant Spleen Target Cells
Effectontarget cell ratio, 20 :1
16 .9% lysis detected with B10.A(4R)-TNP and B10.A(2R)-TNP targets, respec-
tively, map another specificity component to the D end and to modified cell
surface components controlled by the b allele ofH-2D . In contrast to B10.A and
B10.BReffector cells which did not significantly lyse modified targets not sharing
known H-2 alleles with cells of the sensitization phase, but similar to the weak
B10.D2 effector lysis of C57BL/10-TNP targets, C57BL/10 effectors did lyse to a
low, variable and possibly significant extent modified targets which do not share
known H-2 alleles . However, some la antigens, as well as certain serological
specificities are shared between the C57BL/10 cells of the stimulating phase and
these modified targets (i .e ., B10.BR-TNP and B10.A-TNP) (4) .
Effector Cell Specificity Studies Using TNP-Modified Tumor Target
Cells . In the precedingsection effector cell cytotoxicity was observed only if the
spleen target cells were TNP modified and expressed the same K and/or D
regions as the stimulating and/or responding cells . It could be argued that tumor
Responding
cells
Stimulating
cells Target cells Specific
lysis t SE
Target cell H-2 region common
to responding andstimulating
cells
C57BL/10 C57BL/10-TNP C57BL/10 1 .7 f 2 .1 All ofH-2
bbbbbb bbbbbb bbbbbb
C57BL/10-TNP 34 .3 f 2 .7 All of H-2
bbbbbb
B10.A(5R)-TNP 23.9 t2.7 K, I-A, I-B
11 bbbddd
B10.A(4R)-TNP 24 .5 t 1.9 1-C, S, D
kkbbbb
11 11 BIO.A(2R)-TNP 16.9 t 1.5 D
11 kkkddb
B10.BR-TNP 7.5 t 2.4 None
kkkkkk
11 B10.D2-TNP 4.4 t 1.6 None
11 11 dddddd
B10.A-TNP 9.5 t 2.2 None
kkkddd
11 11 C3H.SW-TNP 15 .1 t 1.1 All of H-2
11 11 bbbbbbGENE M. SHEARER, TERRY G. REHN, AND CAROL A. GARBARINO
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cells are more sensitive targets than splenic lymphocytes and that the peculiar
H-2-associated specificity observed may be unique for splenic targets but not for
the more sensitive tumor targets . It might even be possible to detect hapten-spe-
cific (TNP) cytotoxicity using modified tumor target cells . To test these
possibilities B10Á, B10.BR, B10M, and C57BL/10 splenic lymphocytes were
sensitized with TNP-modified autologous spleen cells and the effector cells
generated 5 days later were assayed on unmodified and TNP-modified tumor
targets expressing the same and different H-2 haplotypes as the responding and
stimulating cells . The results of a typical experiment are shown in Table V.
Unmodified target cells were not lysed by the effectors . TNP-modified tumor
target cells expressing the same H-2 as the responding and stimulating cells were
the most effective target cells, and without exception, yielded higher cytotoxic
levels than did modified, non-H-2 compatible tumor targets . However, in con-
trast to the results shown in Tables I-IV using modified spleen cells as targets, a
significant though lesser amount of cytotoxicity was detected when modified
tumor cells not H-2 matched with the cultured cell mixture were used as targets.
TABLE V
In VitroInductionof Cytotoxicity ofB10.A,B10M, B10.D2andC57BL/10 Spleen Cells
to TNP-Modified Autologous Spleen CellsAssayed with TNP-Modified H-2-Matched and
Unmatched Tumor Target Cells
Effectontarget cell ratio, 20 :1
Responder cells Stimulator cells Target cells Specific
lysis f SE
Target cell
H-2haplotype
B10.A (kkkddd) B10.A-TNP (kkkddd) RDM4 2.2 t 2.2 k
"
11 11 11 RDM4-TNP 36.0 t 1 .5 k
" P815-TNP 4.3 t0.5 d
" LSTRA-TNP 6.1 t0.5 d
" EL4-TNP 12.9 t 0.4 b
B10.BR (kkkkkk) B10.BR-TNP (kkkkkk) RDM4 1.4 t 0.9 k
RDM4-TNP 54.3 t3,7 k
P815-TNP 6.2 t 1.2 d
LSTRA-TNP 5.8 t 1.4 d
EL4-TNP 20.3 t 3.9 b
B10.D2 (dddddd) B10.D2-TNP (dddddd) P815 5.0 f 1.2 d
" LSTRA 5 .0 f 1.6 d
" P815-TNP 31 .9f3 .5 d
"
11 11 11 LSTRA-TNP 41 .0 t 1.3 d
" RDM4-TNP 26 .0 t 2.4 k
" EL4-TNP 25 .7 f 1.4 b
C57BL/10 (bbbbbb) C57BL/10-TNP (bbbbbb) EL4 1 .6 :1- 1 .5 b
"
11 11 11 EL4-TNP 40 .7 f 5.4 b
"
11 11 11 P815-TNP 4.5 -t 1.1 d
"
11 11 11 LSTRA-TNP 3.2 f 1.6 d
"
11 11 11 RDM4-TNP 21 .1 f 2.9 k1356
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Cytotoxic levels of 12.9, 20.3, and 29.7% were obtained, respectively, when EL4-
TNP targets were used to assay cultures of B10.A-, B10.BR-, and B10.1)2-re-
sponding and modified stimulating cells . Likewise, RDM4-TNP was an effective
target for detecting cytotoxicity of effectors generated in B10.D2 and C57BL/10
cultures . It is not surprising that RDM4-TNP is an effective target for B10.A cul-
tures, since B10.A expressesKalleles at K, I-A, and I-B .
However, an exception to the H-2-associated cross-reactivity of modified
tumor cells was observed for the two H-2d tumor lines used . Both P815-TNP and
LSTRA-TNP were effective targets only when assayed with effectors generated
from B10.D2 donors . Thus, TNP modified H-2d tumor cell targets behaved more
like the modified spleen targets . Furthermore, P815-TNP and LSTRA-TNP did
not detect cytotoxicity of effector cells generated from B10.A-responding and
B10.A-TNP-stimulating cells. (B10.A spleen and H-2d tumor share D-end
serological specificities.) This observation is also remarkably similar to the
specificity observed with splenic targets but contrasts with the other modified
tumor targets . Finally, the H-2-associated specificity restrictions noted with the
H-2d tumors applies only to H-2d target cells and not to H-2d effectors . The
B10.D2 effectors lysed both RDM4-TNP and EL4-TNP targets .
Verification of Exclusive TNP-Modified K-end Specificity of B10.BR Effector
Cells by Blocking with Modified Nonradioactive Targets . As an independent
verification of preferential specificity of B10.BR lymphocytes towardTNP-modi-
fied K-end components, nonradioactive TNP-modified cells were added to the
"Cr-labeled spleen target and effector cell mixture for the duration of the 4-h
effector phase. The nonradioactive, modified cells added were : (a) BIO.BR-TNP,
which do not discriminate between theKandD ends, since they are syngeneic
with responding and target cells ; or (b) C3H.OH-TNP which should compete for
the modified k allele at the D end only, providing B10.BR lymphocytes are
capable of responding to TNP-modified autologousD region . Results ofa typical
experiment are shown in Table VI . Addition of unlabeled, unmodified cells
TABLE VI
Effect of Adding TNP-Modified, Nonradioactive Target Cells to a Mixture of BIO.BR
Effector Cells and "Cr-Labeled, TNP-Modified BIO.BR Target Spleen Cells
Thenumbers ofeffector and "Cr-labeled target cells mixed in the effector phase were 1 x 101and5 x
104, respectively, i.e., 20 :1 ratio . Cytotoxic levels of B10.BR effector cells assayed on B10.BR-TNP
and C3H.OH-TNP target cells withoutanynonradioactive targetswere 39 .4 and 8.5%, respectively .
Nonradioactive
target cellsadded
to effector phase
(x 10 6)
Unmodified
Lysis t SE
TNPmodified
Reduction in
cytotoxicity
2.5 B10.BR 19 .5 t 3.7 14 .0 t 2.1 28 .2
5.0 B10.BR 29 .1 t 3.9 10.0 t 1.6 66.5
10.0 B10.BR 27 .5 f 1.1 8.0 t 3.3 70.9
2.5 C3H.OH 22 .2 t 1.2 24 .3 t 3.0 -9 .5
5.0 C3H.OH 22 .3 t 2.8 22 .1 t 2.6 0.9
10 .0 C3H.OH 20 .1 t 2.4 23.2 t 3.1 -15.4GENE M . SHEARER, TERRY G . REHN, AND CAROL A . GARBARINO
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tended to reduce the cytotoxic levels from 39.4 to between 19.5 and 29.1%. This
reduction could be due to a crowding effect of the extra cells added to the cyto-
toxic phase . Nonradioactive B10.BR-TNP had an additional effect on reducing
cytotoxic levels . This reduction was a direct function of the number of
nonradioactive B10.BR cells added . In contrast, the addition of unlabeled
C3H.OH-TNP cells to the effector phase had no specific effect on reducing the
cytotoxic level below control values . These results verify that the specificity of
the B10.BR effector lymphocytes is directed toward an entity other than
TNP-modified cell surface components controlled by theK allele of the H-2D .
Demonstration that the H-2K and/or D Homology is Required between
Modified Targets and Modified Stimulating Cells. In preceding sections of this
report H-2K- and/or D-associated homology between TNP-modified stimulating
cells responding lymphocytes was repeatedly demonstrated . None of the results
involving spleen cell targets discriminated among the possibilities that the strict
intra-H-2 homology observed is required : (a) between modified target cells and
responding lymphocytes; (b) between modified target and modified stimulating
cells ; or (c) among all three of these cell types . In order to determine whether
these requirements of specificity are between target and responder cells or
modified target and modified stimulator cells, (C57BL/10 x B10.A)F, lym-
phocytes were sensitized with TNP-modified B10.A or with TNP-modified
C57BL/10-stimulating cells . The effector cells generated from these cultures were
then assayed on TNP-modified target spleen cells from both parents . Ifhomology
were required between target and responding cells, then effectors generated by
sensitization of F, cells with either parent should lyse target cells from either
parent providing that both stimulating and target cells were modified . If,
however, K- and D-region homology were required between modified stimulator
and modified target cells, then lysis of modified parental targets would occur only
when the responding lymphocytes were sensitized with modified spleen cells from
an identical parent . As shown in Table VII, cytotoxicity was obtained only in
those cases in which the modified target and stimulating cells were identical .
These results, therefore, verify the initial interpretation (23) that this phenome-
non involves antigenic recognition ofand response to TNP-altered H-2-controlled
TABLE VII
In Vitro Induction of Cytotoxicity of (B10 x BIO.A)F, Spleen Cells to TNP-Modified BIO
or BIO.A Spleen Cells Assayed with TNP-Modified B10 or B10.A Spleen Cells
Effector:target cell ratio, 20:1
Target cell homology with :
Responding Stimulating Target cells Specific
cells cells lysis t SE Responding Stimulating
cells cells
(B10 x B10.A)F, B10.A-TNP B10.A-TNP 26 .0 f 2.2 Yes Yes
" B10.A-TNP B10-TNP 5.5 t 1.8 Yes No
" B10-TNP B10-TNP 38 .1 t 3.4 Yes Yes
" B10-TNP B10.A-TNP 4.6 t 2.7 Yes No1358
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cell surface components, which are subsequently required as targets for the
stimulated clone(s) of effector cells generated .
Discussion
The data shown throughout this report (with the exception of certain tumor
cell targets, Table V) repeatedly indicate that the cytotoxic specificity of the
thymus-derived effector cells is directed toward altered cell surface components
which map within the murine MHC. By sensitizing splenic lymphocytes with
TNP-modified autologous spleen cells and testing for lympholysis on modified
splenic targets differing from the responding and stimulating cells within H-2, it
was possible to map the particular MHC region responsible for the specificity to
the K end for B10.A and B10.BR, and to both the K and D ends for B10.D2 and
C57BL/10 . Preliminary reports of results similar to a portion of those shown here
have been presented recently (27, 28).
Effector cells generated by sensitization of B10.A and B10.BR lymphocytes
with the respective TNP-modified autologous spleen cells lysed all modified
splenic targets which expressed thek allele in theK andI-A regions (Tables I and
II) . The failure of both of these effectors to lyseA.TL-TNP targets indicated that
modified cell surface components controlled by the k allele of theK region are a
necessary part of this specificity . Since no recombinants were available which
express the k allele in theK region but not in I-A, it was not possible to establish
whether the specificity involved modified components controlled byK alone orK
plus I-A. The failure of B10.A effector cells to lyse B10.D2-TNP and B10.A(5R)-
TNP targets indicated that the specificity of these lymphocytes is directed
primarily toward the K end, and that modified products of I-C, S, andD regions
are not recognized by B10.A-responding cells . The failure ofB10.A to respond to
modified products of D and of I-C and S are verified separately using the
A.TL-TNP and the B10.HTG-TNP and C3H.OH-TNP targets . Similarly, the
fact that B10.BR effector cells did not lyse C3H.OH-TNP targets, which shares
only theD region, nor three other targets, which share no known H-2 regions with
B10.BR, indicate that these responding lymphocytes are exclusively specific for
modified products of the K end of H-2 . This was further verified by the failure
of unlabeled, TNP-modified C3KOH cells to reduce the cytotoxic levels of the
B10.BR effector phase (Table IV).
Restriction of reactivity to altered K-end products, however, is not necessarily
a characterisitic of all mouse strains . BothMOM and C57BL/10 responded as
well to their TNP-modifiedD region dand b alleles as to their respective modified
K ends .MOM effector cells lysed both TNP-modified targets which share only
theD region (A.TL-TNP, Table III) with the sensitizingcells ; andC3H.OH-TNP
which are syngeneic with B10.D2 at all H-2 regions except D . This indicates that
MOM lymphocytes respond to autologous TNP-modified D-region products
and to at least a second TNP-modified autologous specificity mapping to the left
ofH-2D, which could be controlled by H-2K (although this was not proven) . Simi-
larly, C57BL/10 effector cells generated by sensitization with modified autologous
cells lysed B10.A(4R)-TNP and B10.A(2R)-TNP targets, the latter of which
localizes the cytotoxic specificity to modified products of H-2D ; as well as
B10.A(5R)-TNP, which maps a second modified specificity controlled by the bGENE M . SHEARER, TERRY G . REHN, AND CAROL A . GARBARINO
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allele(s) and theK end ofH-2 . Similar observations have been made for cytotoxic
specificity against lymphocytic choriomeningitis virus-infected target cells (29,
30) . Another observation made in the B10.132 and C57BL/10 strains but not seem
in the B10.A and Ll0.BR strains was the weak, variable, and statistically ques-
tionable reactivity observed to some TNP-modified splenic targets which do not
share known H-2 regions with the responding and stimulating cells. If theseweak
responses are real, they may represent reactivities toward TNP-modified la anti-
gens and/or serological specificities shared between the targets and cells of the
stimulating phase.
It is noteworthy that the strict H-2-dependent cytotoxic specificity observed
with modified spleen target cells was not seen when TNP-modified tumor cells
were used as targets . Modified tumor cells (with the exception of H-2d tumors)
not H-2 matched with the cells of the stimulating phase were effective targets,
although not as good as modified H-2-matched tumor cells . This finding
indicates that the tumor targets detected modified H-2-controlled specificity, as
well as nonhistocompatibility-associated specificity . The latter specificity could
be directed toward theTNP hapten exclusively, and might not be detected using
the less sensitive spleen targets . However, such an interpretation would not
accountforthe failure oftwo H-2d tumortargets to be lysed by non-H-2-matched
effectors (see Table V) . The nature of the additional specificity component
detected with H-2k and H-2° TNP-modified tumor target cells remains to be
elucidated . The discrepancy reported here and previously (23) in the ability of
B10.132 effectors to lyse EL4-TNP targets may be due to changes in culture
conditions such as the addition of 2-mercaptoethanol. Since tumor cell targets
are often used for allogeneic T-cell-mediated cytotoxic assays, this comparison of
modified tumor and spleen cells illustrates the importance of using splenic rather
than tumor targets for demonstrating cytotoxic reactivity to H-2-controlled
chemically modified cellular components .
The dependence of lympholysis in this system on H-2 compatibility between
the TNP-modified splenic target cells and the cells of the stimulating phase is
noteworthy . At least two explanations can be given to account for this intra-
H-2 dependency : (a) effector-target cell interaction involving some H-2-con-
trolled surface structure ; or (b) sensitization of the relevant lymphoid clones to
TNP-modified, H-2-controlled autologous cell surface components, leading to
the generation of effector cells specific for and capable of lysing only targets
expressing the same modified H-2-controlled antigenic specificities . The results
shown in Table VII indicate that the second alternative is the correct one, since
cytotoxicity was obtained only when the modified targets were syngeneic with the
modified stimulating cells . Thus, this phenomenon is "autoimmune-like" in that
pre-existing clones of responding lymphocytes react against modified autologous
H-2-controlled self-components . Nevertheless, TNP is necessary in order to
obtain cytolysis, as shown in the first two lines of Tables I-IV . It appears that the
type of modifying agent is also important in determining the antigenic specificity
of the recognition unit (T . G. Rehn et al ., unpublished observations and reference
31), although it has not yet been established whether the modifying agent is an
integral part of the antigen or whether it simply serves as modifier . A similar
interpretation has been made for the H-2-dependent T-cell-mediated cytotoxic-1360
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ity to lymphocytic choriomeningitis virus-infected target cells (32) . It is evident
from Table VII that there are at least two distinct clones of responding
lymphocytes from the F, donors, one recognizing TNP-modified H-26 compo-
nents and the other TNP-modified H-2Q specificities .
The immunogenic entities resulting from TNP modification appear to involve
modified-self' and may represent altered histocompatibility antigens . If new
cellular antigens are created by modification of the H-2 serological specificities,
the remarkable intra-H-2 specificity observed raises the possibility that the
major new determinants formed are restricted to private specificities, since some
public specificities are shared between certain of the effector and target cells
tested (4) . Alternatively, it is possible that new antigens are formed by both
modified private and public specificities . If so, then the mouse strains investi-
gated are mainly responsive to the new cellular antigens resulting from TNP
alteration of privatespecificites, but notto those involving modification of public
specificities, possibly due to lack of expression of the proper Ir genes . Whatever
the cell surface changes resulting from TNP modification are, they do not
detectably affect expression of the H-2 alloantigens involved in either the
sensitization or effector phases of the in vitro cytotoxic response (28) . It has not
been excluded that H-2-dependent modification of cell surface alters H-2
products which heretofore have not been detected .
It is noteworthy that the specificity ofB10.A effector lymphocytes was directed
exclusively toward modified products controlled by the K end, but not to
products of the H-2D region, whereas B10.D2-responding cells sensitized with
TNP-modified autologous cells generated effectors specific for modified K-end
products and for modified D-region products (compare lines 6 and 4 of Tables I
and III, respectively) . Since B10.A and B10.D2 mice share the H-2D region, this
comparison indicates that the lack of reactivity of B10.A splenic lymphocytes to
TNP-modified cell surface components controlled by the d allele ofH-2Dwas not
due to a failure of the creation of a new modified autologous antigen. Further-
more, these observations indicate that formation of a new antigenic specificity is
not sufficient in all instances to generate a cytotoxic response . However, by re-
placing the k alleles at the K, I-A, and I-B regions (BIO.A) with the corresponding
d alleles (BlO.D2), i .e . at intra-H-2 regions not detectably involved in this partic-
ular specificity, a cytotoxic response was obtained . It is noteworthy that the
region(s) responsible for reactivity does not include H-2D, which is associated
with the TNP-modified antigen, but does include the I-A and I-B regions, which
have been shown to control immune responsiveness to a number of immunogens
(1, 14) . Thus, it is probable, but not yet proven that the failure ofB10.A-respond-
ing lymphocytes to generate an in vitro cytotoxic response to TNP-modified
products controlled by the d allele of theD region is due to the lack of expression
of the proper H-2-linked Ir gene(s), which maps in theK end. The gene(s), how-
ever, appears to be expressed in the B10.D2 strain, which differs from B10.A at
I-A and I-B, as well as at K. If Ir genes are involved in controlling sensitization to
TNP-modified autologous cells, this model offers some unique properties which
include the demonstration : (a) of an Ir-gene-controlled primary immune response
in vitro ; (b) of Ir-controlled T-cell-mediated lympholysis which implies an Ir-gene
defect exclusively attributable to a functional thymus-derived cell population ;GENE M . SHEARER, TERRY G . REHN, AND CAROL A . GARBARINO
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and (c) that the MHC can be shown to be involved both in the response potential
to and in the formation ofnew cellular antigenic determinants .
The TNP modification of cells in these experiments is likely to induce many
conformational cell surface alterations which need not necessarily be associated
with the MHC, particularly not with what appear primarily to be private H-2
serological specificities. How, then, might we account for this restriction of
specificity? Restriction of cellular immunity to TNP-modified autologous
products of the serologically defined regions can be accounted for in at leastthree
nonmutually exclusive ways . First, the immune system might be genetically
capable of responding to many altered self-antigens resulting from modification
of H-2 products, but the restriction could be due to the formation of a very
limited number of new antigenic determinants resulting from the modification .
Second, it is possible that many new antigenic determinants are formed as a
result of TNP modification, but the restriction on reactivity may result from a
limited number of H-2-linked Ir genes, which define and limit the number of
distinct and specific clones in the immunological pool of an inbred mouse strain .
Finally, it could be argued that the serologically defined (SD) regions of the
MHC control alloantigenic specificities which are important as cytotoxic effector
cell targets (5), and that the same restrictions apply to TNP-modified autologous
SD-controlled products . At the present time it can be said that at least one
precedent appears to exist in this system, which is compatible with the second
interpretation . Splenic lymphocytes do not respond to TNP-modified autologous
products controlled by the d allele of H-2D, whereas B10.D2 responding
lymphocytes which express different Ialleles and therefore different Ir genes do .
What is the significance of control by the MHC of both the formation ofnew
antigenic specificities and the response potential to these specificities? It may be
that bifunctional histocompatibility linked control of the immune response
involving Ir genes as well as new antigens resulting from modified histocompati-
bility gene products is more general than that demonstrated for TNP-modified
autologous antigens . Such a model could account for multigenic control of
autoimmune thyroiditis (33) and viral-induced leukemia in mice (34-36), as well
as HL-A-associated disease susceptibility in humans (3) .
The possible functional significance of histocompatibility antigens has been
reviewed elsewhere (37) . Snell has considered that histocompatibility antigens
may serve as receptor sites for the attachment of viruses to cell surfaces (38) . In
this model the receptor site was postulated to be essential for infection . The
selective advantage of such a model has been questioned, however, since
heterozygotes would be most susceptible to infectious virus (37) . However, it
should be pointed out that the heterozygote would be at an advantage if the
possibility is now considered that the histocompatibility controlled serological
specificities serve not as receptors for viral infection (and therefore to the agent's
disadvantage), but rather as easily modifiable autologous cell surface structures
which are particularly suited for cell-mediated immune reactions against the
infection . In support of this, lymphocytes from heterozygous F, donors have a
broader range of reactive potential to TNP-modified autologous components
than do the cells from either homozygous parent (A .-M . Schmitt-Verhulst andG.
M . Shearer, unpublished observations) . Susceptibility could result if the proper1362
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serological specificities were not expressed to form immunogenic complexes with
the infectious agents on the cell surface, and/or if the relevant H-2-linked Ir genes
were not expressed. Such a hypothetical mechanism could serve in surveillance
against viral-induced autologous tumors, since it might remove viral-trans-
formed potentially neoplastic cells, and, to the individuals disadvantage, in
autoimmunity .
Based on the results of this report and the above discussion, the following
working hypothesis is proposed : (a) It is probable that the cell surface antigens
controlled by theMHC have some evolutionary and possibly current immunolog-
ical significance . (b) It is improbable that this significance is for allograft
reactivity, since the system evolved in an autologous state, although fetal-mater-
nal interactions may have been important (37) . (c) One autologous function
(based on the results presented here) is that major histocompatibility controlled
serological specificities can serve as cell surface components which are chemi-
cally modifiable, by virus infection or possibly by other means (e.g., autoimmune
complexes) to create new cell-bound antigens which are particularly suitable for
inducing cell-mediated immunity. (d) Whether or not immune reactivity will
result from such alterations depends ; (i) on the expression of immune response
genes which map in the same genetic region, and/or (ii) on the nature of these
new cell-bound antigens . Studies are in progress to test this hypothesis in vitro
and in vivo using a number of chemical-modifying agents and in experimentally
induced autoimmunity .
Summary
Splenic lymphocytes from four C57BL/10 congenic resistant mouse strains
were sensitized in vitro with trinitrophenyl (TNP)-modified autologous spleen
cells . The effector cells generated were incubated with 51Cr-labeled unmodified
or TNP-modified spleen or tumor target cells, and the percentage of specific
lympholysis determined . The results obtained using syngeneic-, congenic-,
recombinant-, and allogeneic-modifiedtarget cells indicatedthatTNP modifica-
tion of the target cells was a necessary but insufficient requirement for
lympholysis . Intro-H-2 homology either between modified stimulating cells and
modified target cells or between responding lymphocytes and modified target
cells was also important in thespecificity for lysis. Homology at theKserological
region or at K plus I-A in the B10.A and B10.BR strains, and at either theD
serological region or at some other region (possibly K) in the B10.D2 and
C57BL/10 strains were shown to be necessary in order to detect lympholysis .
Experiments using (B10.A x C57BL/10)F 1 responding lymphocytes sensitized
and assayed with TNP-modified parental cells indicated that the homology
required for lympholysis was between modified stimulating and modified target
cells . The possibility is raised that histocompatibility antigens may serve in the
autologous system as cell surface components which are modified by viruses or
autoimmune complexes to form cell-bound modified-self antigens, which are
particularly suited for cell-mediated immune reactions. Evidence is presented
suggesting that H-2-linked Ir genes are expressed in the TNP-modified autolo-
gous cytotoxic system . These findings imply that the major histocompatibility
complexcan be functionally involved both in the response potential to and in the
formation of new antigenic determinants involving modified-self components .GENE M . SHEARER, TERRY G . REHN, AND CAROL A . GARBARINO
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